| abstract |
The present invention relates to a binding molecule having one or more epitope binding sites specific for an epitope of CD137 and one or more epitope binding sites specific for an epitope of a tumor antigen ("TA"). (Eg, “CD137 × TA binding molecule”). In one embodiment, such a CD137 × TA binding molecule becomes a bispecific molecule, in particular a bispecific tetravalent diabody, which comprises two, three, four or more polypeptides It has two epitope binding sites consisting of chains and each specific for an epitope of CD137, and two epitope binding sites each specific for an epitope of TA. Alternatively, such a CD137 × TA binding molecule becomes a bispecific molecule, especially a bispecific trivalent diabody, consisting of three or more polypeptide chains and each specific for an epitope of CD137. One or two epitope binding sites, and one or two epitope binding sites, each specific for an epitope of TA. A CD137 × TA binding molecule of the invention can bind to CD137 and TA simultaneously. The present invention is directed to pharmaceutical compositions containing any such CD137 × TA binding molecule. The invention is further directed to methods of using such molecules in treating cancer and other diseases and conditions. The present invention also provides novel CD137- and HER2 / neu-binding molecules, as well as derivatives and uses thereof. [Selection diagram] FIG. |